USPTO serial 88360434
SIMGHRO
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 4, 2023
- Examiner
- LORENZO, GEORGE M
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with SIMGHRO?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Ascendis Pharma Endocrinology Division A/S
Hellerup, DK
Other trademarks owned by Ascendis Pharma Endocrinology Division A/S
Ascendis Pharma Endocrinology Division A/S
Hellerup, DK
Other trademarks owned by Ascendis Pharma Endocrinology Division A/S
Ascendis Pharma Endocrinology Division A/S
Hellerup, DK
Other trademarks owned by Ascendis Pharma Endocrinology Division A/S
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Shannon Marie McKeon
Shannon Marie McKeon DYKEMA GOSSETT PLLC1301 K STR., N.W., SUITE 1100WASHINGTON, DC 20005UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of growth disorders, pharmaceutical preparations for the treatment of endocrine disorders, pharmaceutical preparations for the treatment of bone disorders, pharmaceutical preparations for the treatment of cancer, pharmaceutical preparations for the treatment infectious diseases; diagnostic preparations for medical use, namely, diagnostic preparations for identifying and detecting growth hormone deficiency, endocrine disorders, bone disorders, cancer, and infectious diseases | ACTIVE | — |
| 009 | Downloadable computer software and downloadable computer programs for use in providing medical advice and advice on medications for treatment, patient assistance and health insurance in the field of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases; downloadable computer application software for mobile phones, tablet computers, handheld computers and personal computers, namely, a downloadable software application for sharing information related to growth disorders, endocrine disorders, bone disorders, cancer, infectious diseases and the treatment of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases for use by patients with growth hormone disorders, hypoparathyroidism, skeletal dysplasia, and diabetes in the medical field of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases; downloadable computer application software for mobile phones, tablet computers handheld computers and personal computers, namely, downloadable software that coordinates the delivery of health care services between health care providers, patients and those parties responsible for the payment of health care services, namely, downloadable software that allows individuals seeking medical education, information and services to locate a physician and treatment facility in their geographic area for medical treatment and allows physicians and health care professionals to communicate their credentials and specialization to patients and parties responsible for payment of healthcare services; downloadable computer application software for mobile phones, tablet computers, handheld computers and personal computers, namely, downloadable software that enables health care providers to monitor patients, communicate clinical information relevant to a patient's care, provide and exchange information concerning patients and the health care services provided to patients; downloadable software, downloadable software applications and downloadable mobile applications for providing co-pay and other financial or medical access support; downloadable computer software for providing a communications platform enabling users to share health and healthcare information; downloadable software, downloadable software applications and downloadable mobile applications for the measurement of height, weight, blood pressure, serum calcium, blood glucose, and heart rate; downloadable software, downloadable software applications and downloadable mobile applications for providing, exchanging, retrieving and analyzing health and healthcare information; downloadable software for medical purposes, namely, for formatting, viewing and transmitting medical data collected and stored on hormone injection pens and pumps and between said injection pens and pumps and portable electronic devices; downloadable computer application software for mobile phones, tablet computers, handheld computers and personal computers, namely, a downloadable software application for providing healthcare-related information, medication reminders, and tracking medication dosing history; the foregoing downloadable software related to pharmaceutical preparations for the treatment of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases | ACTIVE | — |
| 010 | Medical devices for injection, dosage and control of pharmaceuticals, namely, medical devices for injection, dosage measurement and monitoring of pharmaceuticals for the treatment of growth disorders, endocrine disorders, bone disorders, cancer, and infectious diseases; syringes for medical purposes and for injections; syringes for injection for medical and surgical use, namely, syringes in the form of pens for surgical use; digitally connected medical devices for monitoring the dispensation of pharmaceutical preparations for use in connection with management of growth hormone disorders, hypoparathyroidism, skeletal dysplasia, cancer and diabetes; medical apparatus, namely, infusion and injection devices for administering drugs; medical apparatus for diagnostic purposes, namely, medicine dosage dispensers containing software featuring web-based medical information for physical and psychological examination and assessment of patients remotely and at a clinic; dosage management dispensers containing software for medical information management for guidance and control of medicines and for therapeutic use in web-based physical and psychological examination and assessment of patients remotely and at a clinic | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Ascendis Pharma Endocrinology Division A/S
- Other trademarks owned by Ascendis Pharma Endocrinology Division A/S
- Other trademarks owned by Ascendis Pharma Endocrinology Division A/S
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Similar marks named SIMGHRO
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 4, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 4, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| May 31, 2023 | DP1B | 1(B) BASIS DELETED; PROCEED TO REGISTRATION | — |
| Apr 13, 2023 | IUCN | NOTICE OF ALLOWANCE CANCELLED | — |
| Apr 13, 2023 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Oct 26, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 25, 2022 | EX5G | SOU EXTENSION 5 GRANTED | — |
| Oct 17, 2022 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| Oct 7, 2022 | EXT5 | SOU EXTENSION 5 FILED | — |
| Oct 7, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 14, 2022 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 12, 2022 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Apr 12, 2022 | EXT4 | SOU EXTENSION 4 FILED | — |
| Apr 12, 2022 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Sep 16, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Sep 14, 2021 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Sep 14, 2021 | EXT3 | SOU EXTENSION 3 FILED | — |
| Sep 14, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Apr 14, 2021 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Apr 12, 2021 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Apr 12, 2021 | EXT2 | SOU EXTENSION 2 FILED | — |
| Apr 12, 2021 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Oct 15, 2020 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Oct 13, 2020 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Oct 13, 2020 | EXT1 | SOU EXTENSION 1 FILED | — |
| Oct 13, 2020 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 4, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 14, 2020 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Feb 18, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 18, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 29, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 13, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 13, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 13, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 7, 2020 | ALIE | ASSIGNED TO LIE | — |
| Dec 16, 2019 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Jun 12, 2019 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jun 12, 2019 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jun 12, 2019 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jun 12, 2019 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 12, 2019 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 12, 2019 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 12, 2019 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jun 10, 2019 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 10, 2019 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 10, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 9, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 15, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 1, 2019 | NWAP | NEW APPLICATION ENTERED | — |